3^rd World Heart and Brain Congress

CNS Biomarkers: Drug Discovery, Research and Development

The term Biomarker can be characterized as a quantifiable marker of some organic state or condition. A biomarker can likewise be known as an organic biomarker. Meetings revolve around the advancement of CNS biomarkers for pharmaceuticals and diagnostics from Cerebrospinal fluid and Blood, and in addition imaging approaches. Logical information, updates and contextual analyses in neurological and neurodegenerative illnesses will be introduced on sickness regions, for example, Alzheimer's and Parkinson's.

• Cerebrospinal fluid biomarkers
• Neuroimaging enrichment biomarkers for CNS diseases
• Biomarker Challenges in Rare Diseases
• Technology case studies for CNS
• CNS drug development using biomarkers

Advances in multimodality fusion imaging technologies promise to accelerate the understanding of the systems biology of disease and help in the development of new therapeutics. The use of molecular imaging biomarkers has been proven to shorten cycle times for central nervous system (CNS) drug development and thereby increase the efficiency and return on investment from research. Imaging biomarkers can be utilized to help choose the molecules, doses, and patients well on the way to test remedial speculations by ceasing those that have minimal possibility of achievement and accelerating those with potential to achieve beneficial clinical outcomes. CNS imaging biomarkers have the potential to drive new medical care practices for patients in the latent phases of progressive neurodegenerative disorders by enabling the detection, preventative treatment, and tracking of disease in a paradigm shift from today's approaches that have to see the overt symptoms of disease before treating it.